Kit and method for detecting inhibition condition of dust mite specific blocking antibody on basophilic granulocyte activation and application
The kit for basophil activation detection directly reflects the inhibitory effect of dust mite-specific blocking antibodies, solves the complex and inaccurate problems of the existing technology, and realizes simple and accurate blocking antibody function evaluation. Suitable for guiding clinical allergen-specific immunotherapy.
Patent Information
- Application Number
- CN202411200782.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
AI Technical Summary
The existing methods for detecting blocking antibodies are complex and inaccurate enough to directly reflect the inhibitory effect of dust mite-specific blocking antibodies on basophil activation, especially in allergen-specific immunotherapy, which is difficult to effectively evaluate. Treatment effect.
Provide a kit containing basophils, dust mite allergens and fluorescently labeled anti-human CD63 antibodies. By detecting basophil activation, it directly reflects the inhibitory effect of dust mite-specific blocking antibodies, which is easy to operate. And accurate.
Without the need to culture EBV-transformed B cells or high concentration specific IgE serum, the inhibitory effect of dust mite-specific blocking antibodies is directly evaluated. It is suitable for evaluating the effect of allergen-specific immunotherapy, simplifying the operation process and improving the accuracy of detection. sex.
Smart Images

Figure CN119044483A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a kit, method and application for detecting the inhibition of basophil activation by dust mite-specific blocking antibodies. Background Art
[0002] Allergic asthma is a heterogeneous disease characterized by chronic inflammation of the airways involving multiple cells, such as mast cells, eosinophils, basophils, T lymphocytes, and airway epithelial cells. The treatment of allergic asthma follows the guidelines of the Global Initiative for Asthma (GINA) to administer drugs such as glucocorticoids. For allergic patients with clear allergens, allergen-specific immunotherapy (AIT) can also be performed. AIT refers to repeated exposure of allergic patients to gradually increasing doses of allergens to improve patients' tolerance to such allergens (Durham SR, et al. Nat Rev Immunol. 2023; 23(5): 317-328). The mechanism of action of AIT includes: inducing the production of T regulatory cells (Treg), which regulate the conversion of Th2-type cell immunity to Th1-type cell immunity, and regulating the production of interleukin-10, inducing the production of allergen-specific immunoglobulin G (sIgG); sIgG can specifically bind to allergens to form allergen-sIgG complexes, which can effectively reduce allergens around effector cells such as basophils without causing cell activation effects, and inhibit the release of intracellular inflammatory mediators. Therefore, sIgG is considered to be a blocking antibody, and the increase of its subtype sIgG4 is currently the most significant antibody change in AIT.
[0003] Studies have shown that after AIT treatment of house dust mites, the level of house dust mite sIgG4 in asthma patients increased, and the immunoglobulin E (IgE)-mediated allergen binding test confirmed that the ability of serum house dust mite sIgG4 to block the binding of IgE to house dust mite allergens was enhanced (Mulin Feng, et al. Journal of Immunology, 2018; 200: 3897-3904). However, the amount of sIgG4 produced after AIT is inconsistent with the clinical efficacy. It is speculated that this may be because the blocking antibodies produced after AIT also include IgA and IgD, and at the same time, it may be related to changes in IgG binding ability. On the other hand, single house dust mite immunotherapy, in addition to the increase of house dust mite-specific IgG4, can also cause an increase in dust mite-specific IgG4. This may be caused by cross-reactions caused by different types of dust mites having the same or similar antigenic epitopes. Specific blocking antibodies of different types of dust mites may also inhibit the activation of basophils by dust mite allergens with the same or similar antigenic epitopes. Therefore, detecting the blocking function of blocking antibodies may better reflect the therapeutic effect of AIT. However, the current method for evaluating the function of blocking antibodies is mainly the IgE-mediated allergen binding test, which uses B cells transformed by EBV (Epstein-Barr virus) and utilizes the IgE low-binding receptor (immunoglobulin E Fc segment receptor II, FcεRⅡ) expressed on the surface of B cells for detection, indirectly reflecting the function of blocking antibodies in inhibiting effector cells such as basophils; and this method requires culturing B cells to express FcεRⅡ at an expression rate of more than 95%, and requires serum containing high concentrations of specific IgE as the mediating antibody that binds to FcεRⅡ. Summary of the invention
[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a simple and accurate kit, method and application for detecting the inhibition of basophil activation by dust mite-specific blocking antibodies.
[0005] To achieve the above object, the technical solution adopted by the present invention is:
[0006] In a first aspect, the present invention provides a kit for detecting the inhibition of basophil activation by dust mite-specific blocking antibodies, characterized in that the kit contains basophils, dust mite allergens and anti-human CD63 antibodies.
[0007] The present invention directly reflects the function of dust mite-specific blocking antibodies in inhibiting the activation of effector cells by detecting the activation of basophils, and the operation is simple and accurate.
[0008] Furthermore, the kit also contains a positive control reagent and a negative control reagent, wherein the positive control reagent contains dust mite-specific immunoglobulin G (IgG), and the negative control reagent contains phosphate buffered saline (PBS).
[0009] Furthermore, the anti-human CD63 antibody is fluorescently labeled, and the fluorescent label is at least one of fluorescein isothiocyanate (FITC), phycoerythrin (PE) and allophycocyanin (APC).
[0010] Furthermore, the basophils are isolated from patients allergic to dust mite allergens.
[0011] The proportion of cells with double positive CD123 and IgE on the surface of the basophils is greater than 95%, and the surface of the basophils expresses the IgE high affinity receptor (FcεRI), and the FcεRI expressed on the surface of the basophils is bound to dust mite-specific IgE. FcεRI is stably expressed in basophils, and dust mite allergens can cause cross-linking of the FcεRI-IgE complex on the cell surface, triggering intracellular signal cascade reactions and activating basophils.
[0012] The basophils are specific to dust mite allergens. After being stimulated by dust mite allergens, the basophils are activated and express CD63 molecules on the cell surface. CD63 molecules are four transmembrane proteins that are not expressed on the surface of static basophils, but are upregulated on the surface of activated cell basophils.
[0013] Furthermore, the dust mite-specific blocking antibody comprises at least one of immunoglobulin G, immunoglobulin G subtype, immunoglobulin G fragment, immunoglobulin A, immunoglobulin A subtype and immunoglobulin D.
[0014] Furthermore, the immunoglobulin G subtype includes at least one of immunoglobulin G1 (IgG1), immunoglobulin G2A (IgG2A) and immunoglobulin G4 (IgG4).
[0015] Furthermore, the immunoglobulin G fragment includes F(ab')2 and / or F(ab').
[0016] Furthermore, the immunoglobulin A subtype includes IgA1 and / or IgA2.
[0017] Furthermore, the dust mite is at least one of house dust mite, dust mite farinae, European dust mite, micro-corner dust mite, silk dust mite and tropical clawless mite.
[0018] In a second aspect, the present invention provides a method for detecting the inhibition of basophil activation by dust mite-specific blocking antibodies, using the kit for detection.
[0019] Further, the following steps are included:
[0020] S1: mixing dust mite allergens with the sample to be tested, incubating, and obtaining a dust mite allergen incubated sample;
[0021] S2: mixing the basophils with the dust mite allergen incubated reagent in step S1, incubating, washing, and performing solid-liquid separation to obtain incubated basophils;
[0022] S3: mixing the anti-human CD63 antibody with the basophils incubated in step S2, incubating, and washing to obtain basophils labeled with the anti-human CD63 antibody;
[0023] S4: Fix the basophils labeled with the anti-human CD63 antibody in step S3, and detect and analyze the activation of basophils by flow cytometry.
[0024] Furthermore, in step S1, the sample to be tested may be serum of a patient undergoing dust mite allergen-specific immunotherapy, or purified dust mite-specific blocking antibodies.
[0025] Furthermore, in step S1, a positive control reagent and a negative control reagent are also provided, wherein the positive control reagent contains dust mite-specific immunoglobulin G (IgG), and the negative control reagent contains phosphate buffered saline (PBS). Dust mite allergens are mixed with the positive control reagent and the negative control reagent, respectively, and incubated to obtain control samples after dust mite allergen incubation.
[0026] Furthermore, the positive control reagent dust mite-specific immunoglobulin G includes immunoglobulin G, immunoglobulin G subtypes and immunoglobulin G fragments.
[0027] Furthermore, the immunoglobulin G subtype includes at least one of immunoglobulin G1 (IgG1), immunoglobulin G2A (IgG2A) and immunoglobulin G4 (IgG4).
[0028] Furthermore, the immunoglobulin G fragment includes F(ab')2 and / or F(ab').
[0029] Furthermore, in step S1, the dust mite allergen concentration is 0.05-0.6 μg / mL, preferably 0.3 μg / mL. The dust mite allergen volume is the same as that of the sample to be tested, the positive control reagent and the negative control reagent.
[0030] Furthermore, in step S1, the concentration of the dust mite-specific immunoglobulin G is 5 to 30 μg / mL, preferably 10 μg / mL.
[0031] Furthermore, in step S1, the incubation temperature is 26-40°C, preferably 37°C.
[0032] Furthermore, in step S1, the incubation time is 0.5 to 2 hours, preferably 1 hour.
[0033] Furthermore, in step S2, the basophil concentration is 1×10 5 ~1×10 7 / ml, preferably 2×10 6 Pieces / ml.
[0034] Furthermore, in step S2, the incubation temperature is 26-40°C, preferably 37°C.
[0035] Furthermore, in step S2, the incubation time is 15 to 60 minutes, preferably 30 minutes.
[0036] Furthermore, in step S2, the cleaning solution used for cleaning is a PBS solution containing diethylaminetetraacetic acid (EDTA), and the concentration of EDTA is 0.01-0.03 mol / L, preferably 0.02 mol / L.
[0037] Furthermore, in step S2, the amount of PBS solution containing diethylaminetetraacetic acid (EDTA) is 1-3 mL, preferably 2 mL.
[0038] Furthermore, in step S2, the solid-liquid separation is centrifugation; the centrifugation conditions are 200-1000 g, 3-20 min, preferably 300 g, 10 min.
[0039] Furthermore, in step S3, the anti-human CD63 antibody is fluorescently labeled, and the fluorescent label is at least one of fluorescein isothiocyanate (FITC), phycoerythrin (PE) and allophycocyanin (APC), preferably FITC.
[0040] Furthermore, in step S3, the incubation time is 15 to 60 minutes, preferably 30 minutes, and the incubation temperature is 4°C.
[0041] Furthermore, in step S4, the cleaning solution used for cleaning is a PBS solution containing fetal bovine serum (FBS). The volume concentration of the fetal bovine serum is 0.05-10%, preferably 1%.
[0042] Furthermore, in step S4, the amount of PBS solution containing fetal bovine serum (FBS) is 1-3 mL, preferably 2 mL.
[0043] Furthermore, in step S4, the fixative used is paraformaldehyde, and the mass concentration of the paraformaldehyde is 0.05-4%, preferably 1%.
[0044] Furthermore, in step S4, the amount of the fixing solution is 100-500 μl, preferably 300 μl.
[0045] Taking CD63 positive cells as activated cells, the activation rate of basophils = (number of CD63 positive cells / total number of basophils) × 100%. The lower the activation rate of basophils, the stronger the effect of dust mite-specific blocking antibodies in inhibiting basophil activation.
[0046] In a third aspect, the present invention provides the use of the kit in preparing a product for screening dust mite-specific blocking antibodies for treating allergic diseases caused by dust mites and / or evaluating the effect of dust mite allergen-specific immunotherapy. The effect of dust mite allergen-specific immunotherapy is evaluated by detecting the strength of the ability of dust mite-specific blocking antibodies to inhibit basophil activation after dust mite allergen-specific immunotherapy. Evaluating the ability of different types of dust mite-specific blocking antibodies to inhibit basophil activation by dust mites with the same or similar epitopes is beneficial to studying cross-reactions between dust mite antigen components.
[0047] Furthermore, the allergic disease caused by dust mites includes at least one of allergic asthma, rhinitis and chronic urticaria.
[0048] Furthermore, the dust mite is at least one of house dust mite, dust mite farinae, European dust mite, micro-corner dust mite, silk dust mite and tropical clawless mite.
[0049] Compared with the prior art, the present invention has the following beneficial effects:
[0050] The present invention directly reflects the function of dust mite-specific blocking antibodies in inhibiting the activation of effector cells by detecting the activation of basophils. There is no need to culture B cells transformed by EBV, there is no need to culture B cells expressing more than 95% of FcεRⅡ, and there is no need to use serum containing high concentration of specific IgE as a mediating antibody bound to FcεRⅡ. The operation is simple and accurate, suitable for evaluating the effect of dust mite allergen-specific immunotherapy, and is conducive to guiding clinical dust mite allergen-specific immunotherapy. Evaluating the ability of different types of dust mite-specific blocking antibodies to inhibit dust mites with the same or similar epitopes from activating basophils is conducive to studying the cross-reaction between dust mite antigen components. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 This figure shows the result of detecting the functional changes of blocking antibodies in serum in patients allergic to house dust mite allergens by inhibiting basophil activation through dust mite-specific blocking antibodies.
[0052] Figure 2In order to inhibit basophil activation by dust mite-specific blocking antibodies, the results of blocking basophil activation by house dust mite class I allergen (Der p 1)-specific antibody IgG1 (Der f 1-IgG1) and tropical Acyrthosaurus allergen (Blo t 5)-specific antibody IgG1 (Blo t 5-IgG1) were compared. DETAILED DESCRIPTION
[0053] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific examples. Other materials, reagents, etc. used in the examples, unless otherwise specified, can be obtained from commercial sources.
[0054] Example 1 Detection of changes in the blocking function of dust mite-specific blocking antibodies before and after allergen-specific immunotherapy
[0055] 1. Experimental Methods
[0056] 1. Collect candidate serum
[0057] Serum was collected from 20 patients with allergic asthma who received house dust mite specific immunotherapy before treatment, 3 months, 6 months and 12 months after treatment.
[0058] 2. Preparation of basophils
[0059] The peripheral blood of patients allergic to house dust mite allergens was treated with a human basophil isolation kit (manufacturer: EasySep, catalog number: 17969) to obtain basophils from patients allergic to house dust mite allergens, and the basophils were routinely cryopreserved to obtain frozen basophils from patients allergic to house dust mite allergens. 6 Cells / ml) were quickly melted in a 37°C water bath, transferred to a 5 ml flow tube, 2 ml of 4°C phosphate buffer (PBS, 0.01 M, pH 7.2) was added, centrifuged at 300 g for 10 min, washed twice, the supernatant was discarded, the cells were counted, PBS was added, and the cell concentration was adjusted to 2×10 6 / ml, and keep at 4℃ for later use.
[0060] 3. Take a 5 ml flow tube, set up a test sample tube, a positive control tube, and a negative control tube, and add 20 μl of the test sample (serum collected in step 1), 20 μl of the positive control (house dust mite class I allergen-specific antibody IgG1, i.e. Der p 1-IgG1, 10 μg / ml; manufacturer: inbio, product number: MA-10B9), and 20 μl of the negative control (PBS solution, 0.01 M, pH 7.2), respectively; then add 20 μl of house dust mite class I allergen (0.3 μg / mL, manufacturer: inbio, product number: AS-DP1) to each tube and incubate at 37°C for 1 hour.
[0061] 4. Add 20 μl of basophils prepared in step 2 to each tube treated in step 3 and incubate at 37°C for 30 min.
[0062] 5. Add 2 ml of PBS washing solution containing diethylaminetetraacetic acid (EDTA, 0.02 mol / L) at 4°C to each tube treated in step 4 to terminate the reaction and wash the cells. Centrifuge at 300 g for 10 min and discard the supernatant.
[0063] 6. Add 10 μl of FITC fluorescent-labeled anti-human CD63 antibody (CD63-FITC, 0.1 mg / ml) to each tube treated in step 5 and incubate at 4°C for 30 min.
[0064] 7. Add 2 ml of PBS containing fetal bovine serum (FBS, volume concentration is 1%) to each tube treated in step 6, centrifuge at 300 g for 10 min, discard the supernatant, and wash twice.
[0065] 8. Add 300 μl of 1% paraformaldehyde fixative to each tube treated in step 7 to obtain fixed cells.
[0066] 9. Remove cell adhesion and debris after fixation in step 8 and perform flow cytometry detection and analysis.
[0067] The analytical method for flow cytometry detection is:
[0068] Taking CD63 positive cells as activated cells, the activation rate of basophils = (number of CD63 positive cells / total number of basophils) × 100%. The lower the activation rate of basophils, the stronger the function of the blocking antibody.
[0069] 2. Experimental Results
[0070] like Figure 1As shown in the figure, the activation rate of basophils in patients with house dust mite allergen allergy after house dust mite allergen specific immunotherapy was significantly lower than that before house dust mite allergen specific immunotherapy (compared with before treatment, i.e., 0 month, * indicates P<0.05, *** indicates P<0.001), indicating that house dust mite specific immunotherapy produced blocking antibodies that can inhibit the activation of basophils in patients with house dust mite allergen allergy, thereby inhibiting the activation of basophils in patients with house dust mite allergen allergy to produce inflammatory factors.
[0071] Example 2 compares the ability of Der f 1-specific antibody IgG1 (Der f 1-IgG1) and Blo t 5-specific antibody IgG1 (Blo t 5-IgG1) to block the activation of basophils in patients allergic to house dust mite allergens by Der p 1.
[0072] 1. Experimental Methods
[0073] Sample preparation: Der f 1-IgG1 (manufacturer: inbio, catalog number: MA-6A8) and Blo t 5-IgG1 (manufacturer: inbio, catalog number: MA-4D9) were adjusted to the same concentration (10 μg / ml), and three replicates were made for each sample.
[0074] According to the method of Example 1, the sample was tested.
[0075] 2. Experimental Results
[0076] like Figure 2 As shown, the activation rate of basophils in patients allergic to house dust mite allergens in the negative control PBS was detected to be 72.3%, the activation rate of basophils in patients allergic to house dust mite allergens in the positive control Der p 1-IgG1 was detected to be 27.3%, the activation rate of basophils in patients allergic to house dust mite allergens in the Der f 1-IgG1 was detected to be 31.5%, and the activation rate of basophils in patients allergic to house dust mite allergens in Blot 5-IgG1 was detected to be 45.9%.
[0077] The results showed that at the same concentration, Der f 1-IgG1 and Blo t 5-IgG1 could block Der p 1 from activating basophils in patients allergic to house dust mite allergens, indicating that Der f 1-IgG1 and Blo t 5-IgG1 could bind to the same or similar epitopes of Der p 1; and Der f 1-IgG1 could bind to more antigenic epitopes of Der p 1 than Blo t 5-IgG1. Der f 1, Blo t 5 and Der p 1 have the same or similar epitopes and have cross-reactions.
[0078] Example 3 A kit for detecting basophil activation
[0079] 1. Composition
[0080] 1. Basophils from patients allergic to house dust mite allergens, house dust mite allergens, and anti-human CD63 antibodies labeled with FITC fluorescence.
[0081] 2. Positive control reagent: house dust mite allergen-specific antibody IgG1 (can also be IgG2A, IgG4, F(ab')2 and F(ab')); negative control reagent: PBS solution (0.01M, pH 7.2).
[0082] 3. Cleaning solution I: PBS solution (0.01M, pH 7.2) containing 0.02 mol / L EDTA; Cleaning solution II: PBS solution containing 1% FBS.
[0083] 4. Fixative: 1% paraformaldehyde.
[0084] 2. Usage
[0085] 1. Collect the sample to be tested (serum or dust mite-specific blocking antibody to be tested).
[0086] 2. Prepare basophils for patients allergic to house dust mite allergens:
[0087] The frozen basophils from patients allergic to house dust mite allergens were quickly thawed in a 37°C water bath, transferred to a 5 ml flow cytometry tube, added with 2 ml of 4°C PBS, centrifuged at 300 g for 10 min, washed twice, discarded the supernatant, counted the cells, added with PBS (0.01 M, pH 7.2), and adjusted the cell concentration to 2 × 10 6 / ml, and keep at 4℃ for later use.
[0088] 3. Take a 5 ml flow tube, set up a test sample tube, a positive control tube, and a negative control tube, and add 20 μl of the test sample (the sample to be tested collected in step 1), 20 μl of the positive control (10 μg / ml), and 20 μl of the negative control, respectively; add 20 μl of 0.3 μg / mL house dust mite allergen to each tube and incubate at 37°C for 1 hour.
[0089] 4. Add 20 μl of basophils from patients allergic to house dust mite allergens prepared in step 2 to each tube treated in step 3, and incubate at 37° C. for 30 min.
[0090] 5. Add 4°C cleaning solution I to each tube treated in step 4 to terminate the reaction and wash the cells. Centrifuge at 300g for 10 min and discard the supernatant.
[0091] 6. Add FITC fluorescent-labeled anti-human CD63 antibody (CD63-FITC) to each tube treated in step 5 and incubate at 4°C for 30 min.
[0092] 7. Add cleaning solution II to each tube treated in step 6 and clean twice.
[0093] 8. Add 300 μl of fixative solution to each tube treated in step 7 to obtain fixed cells.
[0094] 9. Remove cell adhesion and debris after fixation in step 8 and perform flow cytometry detection and analysis.
[0095] The analytical method for flow cytometry detection is:
[0096] Taking CD63 positive cells as activated cells, the activation rate of basophils = (number of CD63 positive cells / total number of basophils) × 100%. The lower the activation rate of basophils, the stronger the ability of the house dust mite-specific blocking antibody to inhibit basophil activation.
[0097] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A kit for detecting the inhibition of basophil activation by dust mite-specific blocking antibodies, characterized in that: The kit contains basophils, dust mite allergens and anti-human CD63 antibodies.
2. The kit according to claim 1, characterized in that The kit also contains a positive control reagent and a negative control reagent. The positive control reagent contains dust mite-specific immunoglobulin G, and the negative control reagent contains a phosphate buffer solution.
3. The kit according to claim 1, characterized in that The anti-human CD63 antibody carries a fluorescent marker, and the fluorescent marker is at least one of fluorescein isothiocyanate, phycoerythrin and allophycocyanin.
4. The kit according to claim 1, characterized in that The basophils are separated from patients who are allergic to dust mite allergens.
5. The kit according to claim 1, characterized in that The dust mite specific blocking antibody comprises at least one of immunoglobulin G, immunoglobulin G subtype, immunoglobulin G fragment, immunoglobulin A, immunoglobulin A subtype and immunoglobulin D.
6. The kit according to claim 1, characterized in that The dust mite is at least one of house dust mite, dust mite farinae, European dust mite, micro-corner dust mite, silk dust mite and tropical clawless mite.
7. A method for detecting the inhibition of basophil activation by dust mite-specific blocking antibodies, characterized in that: The detection is performed using the kit described in any one of claims 1 to 6.
8. The method according to claim 7, characterized in that The following steps are involved: S1: mixing dust mite allergens with the sample to be tested, incubating, and obtaining a dust mite allergen incubated sample; S2: mixing the basophils with the dust mite allergen incubated reagent in step S1, incubating, washing, and performing solid-liquid separation to obtain incubated basophils; S3: mixing the anti-human CD63 antibody with the basophils incubated in step S2, incubating, and washing to obtain basophils labeled with the anti-human CD63 antibody; S4: Fix the basophils labeled with the anti-human CD63 antibody in step S3, and detect and analyze the activation of basophils by flow cytometry.
9. Use of the kit according to any one of claims 1 to 6 in preparing a product for screening dust mite-specific blocking antibodies for treating allergic diseases caused by dust mites and / or evaluating the effect of dust mite allergen-specific immunotherapy.
10. The use according to claim 9, characterized in that: The allergic disease caused by dust mites includes at least one of allergic asthma, rhinitis and chronic urticaria.
Citation Information
Cited By
Single-tube multi-allergen specific basophilic granulocyte detection method based on multicolor flow cytometry
CN121540611A
